Background and purpose: A nonpsychoactive constituent of the cannabis plant, cannabidiol has been demonstrated to have low affinity for both cannabinoid CB 1 and CB 2 receptors. We have shown previously that cannabidiol can enhance electrically evoked contractions of the mouse vas deferens, suggestive of inverse agonism. We have also shown that cannabidiol can antagonize cannabinoid receptor agonists in this tissue with a greater potency than we would expect from its poor affinity for cannabinoid receptors. This study aimed to investigate whether these properties of cannabidiol extend to CB 1 receptors expressed in mouse brain and to human CB 2 receptors that have been transfected into CHO cells. Experimental approach: The [
Introduction
Cannabis sativa is now known to contain at least 70 compounds that are unique to it and known collectively as cannabinoids (ElSohly and Slade, 2005) . One of these is (-)-D 9 -tetrahydrocannabinol (D 9 -THC), the main psychoactive constituent of cannabis, and another is (-)-cannabidiol, which is not psychoactive and exhibits much lower affinity than D
9
-THC for cannabinoid CB 1 and CB 2 receptors (Showalter et al., 1996; Thomas et al., 1998; Pertwee, 1999; Bisogno et al., 2001; Thomas et al., 2004) . Cannabidiol is of interest because it lacks psychoactivity and yet has therapeutic potential, for example for the management of inflammation, anxiety, emesis and nausea, and as a neuroprotective agent (Pertwee, 2004) . Indeed, together with -THC, cannabidiol is a major constituent of Sativex, a medicine that is now licensed in Canada for neuropathic pain associated with multiple sclerosis.
In previous experiments (Pertwee et al., 2002) , cannabidiol was found to share the ability of the CB 1 -selective inverse agonist/antagonist, rimonabant, to increase the amplitude of electrically evoked contractions of the mouse vas deferens (Pertwee et al., 2002) , which, for rimonabant at least, is most likely an indication of inverse agonist activity (Pertwee, 2005) . Cannabidiol was also found to resemble rimonabant in its ability to antagonize (R)-( þ )-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (R-( þ )-WIN55212)-and (À)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP55940)-induced inhibition of electrically evoked contractions of the mouse vas deferens in a competitive, surmountable manner (Pertwee et al., 1995 (Pertwee et al., , 2002 . Unlike rimonabant, however, cannabidiol produced this antagonism at concentrations well below those at which it binds to CB 1 (or CB 2 ) cannabinoid receptors, suggesting that it was competing with R-( þ )-WIN55212 and CP55940 for an as yet uncharacterized non-CB 1 pharmacological target on nerve terminals. These properties of cannabidiol prompted this current study.
Thus, the present investigation was directed primarily at investigating whether the unexpectedly high potency exhibited by cannabidiol as an antagonist of cannabinoid receptor agonists in the mouse vas deferens extends to cannabinoid receptors in mouse brain tissue and/or to Chinese hamster ovary cells stably transfected with human CB 2 receptors (hCB 2 -CHO) cell membranes. Cannabidiol was compared with rimonabant in the brain tissue experiments and with N-[(1S)-endo-1,3,3-trimethyl bicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528), an established CB 2 receptor inverse agonist/antagonist in the experiments performed with hCB 2 -CHO cell membranes. We also addressed the question of whether cannabidiol behaves as an inverse agonist or as a neutral antagonist at CB 1 and/or CB 2 receptors. Accordingly, in some experiments cannabidiol was compared with a putative neutral cannabinoid receptor antagonist, the synthetic cannabidiol analogue, O-2654 (Thomas et al., 2004) . This compound differs from cannabidiol and rimonabant by behaving as a neutral antagonist of cannabinoid receptor agonists rather than as an inverse agonist in the mouse isolated vas deferens (Pertwee, 2005) .
In this study, we report first that cannabidiol can behave as an inverse agonist at the human CB 2 receptor. Second, we demonstrate that cannabidiol behaves as a high-potency antagonist of cannabinoid receptor agonists in mouse brain tissue and in membranes from CHO cells transfected with human CB 2 receptors. Furthermore, the high potency of cannabidiol as an antagonist of the cannabinoid receptor agonist CP55940 in the hCB 2 -CHO cell membranes appears to be a consequence of the ability of cannabidiol to behave as an inverse agonist at the hCB 2 receptor. Some of the results described in this paper have been presented to the International Cannabinoid Research Society (Thomas et al., 2006) .
Materials and methods
The methods used comply with the UK Animals (Scientific Procedures) Act, 1986 and associated guidelines for the use of experimental animals. Animals MF1 mice were purchased from Harlan UK Ltd (Blackthorn, UK), whereas C57BL/6 CB 1 receptor knockout mice and the wild-type (WT) littermates were obtained from NIH (Rockville, MD, USA). Mice were maintained on a 12/12 h light/ dark cycle with free access to food and water.
CHO cells CHO cells stably transfected with cDNA encoding human cannabinoid CB 2 receptors were maintained in Dulbecco's modified Eagles's medium (DMEM) nutrient mixture F-12 HAM, supplemented with 2 mM L-glutamine, 10% fetal bovine serum (FBS), 0.6% penicillin-streptomycin, hygromycin B (300 mg ml
À1
) and geneticin (600 mg ml À1 ). The CHO cells stably transfected with cDNA-encoding human cannabinoid CB 1 receptors (B max ¼ 29807802 fmol mg À1 protein)
were maintained in DMEM F-12 supplemented with 10% FBS, geneticin (400 mg ml
) and zeocin (250 mg ml
). The native CHO cells were maintained in DMEM nutrient mixture F-12 HAM, which was supplemented with 2 mM L-glutamine, 5% FBS and 2% penicillin-streptomycin. All cells were maintained at 371C and 5% CO 2 in their respective media and were passaged twice a week using non-enzymatic cell dissociation solution. performed with mouse whole-brain membranes, prepared as described by Thomas et al. (2004) , or with native CHO cell membranes, or with membranes from CHO cells transfected with either human CB 1 or CB 2 receptors (Ross et al., 1999) . The buffers used in the preparation of [ 35 S]GTPgS-binding assay brain membranes were additionally supplemented with 100 mM NaCl 2 . The CHO cells were removed from flasks by scraping and then frozen as a pellet at À201C until required. The CB 1 -CHO cells were additionally FBS-starved for 24 h before their removal from flasks. Before use in a radioligand-binding assay, cells were defrosted, diluted in 50 mM Tris buffer (radioligand displacement assay) or GTPgS-binding buffer ([ 35 S]GTPgS-binding assay) and homogenized with a 1 ml hand-held homogenizer. Protein assays were performed using a Bio-Rad Dc kit (Bio-Rad, Hercules, CA, USA).
Membrane preparation

Radioligand displacement assay
The assays were carried out with [ 3 H]CP55940, 1 mg ml À1 bovine serum albumin (BSA) and 50 mM Tris buffer, total assay volume 500 ml, using the filtration procedure described previously (Ross et al., 1999; Thomas et al., 2005 ) to remove endogenous adenosine. All drugs, with the exception of morphine, were stored as a stock solution of 1 or 10 mM in DMSO. The vehicle concentration in experiments conducted using one of these drugs was 0.1% DMSO or 0.11% DMSO in the presence of an antagonist. In experiments with morphine, which was stored as a stock solution of 10 mM in distilled water, we used a vehicle concentration of 0.01% DMSO. (Ross et al., 1999) . These values were compared with the level of basal binding by performing a one-sample t-test (GraphPad Prism). A P-value o0.05 was considered to be significant. Values for EC 50 , for maximal effect (E max ) and for the s.e.m. or 95% confidence limits of these values have been calculated by nonlinear regression analysis using the equation for a sigmoid concentration-response curve (GraphPad Prism).
Analysis of data
The apparent dissociation constant (K B ) values for antagonism of agonists by cannabidiol, rimonabant, SR144528 or O-2654 have been calculated by Schild analysis from the concentration ratio, defined as the concentration of an agonist that elicits a response of a particular size in the presence of a competitive reversible antagonist at a concentration, B, divided by the concentration of the same agonist that produces an identical response in the absence of the antagonist. The methods used to determine concentration ratios and apparent K B values and to establish whether log concentration-response plots deviated significantly from parallelism are detailed elsewhere (Pertwee et al., 2002 ) from PerkinElmer (Boston, MA, USA). GTPgS, adenosine deaminase and hygromycin B from Roche Diagnostic (Indianapolis, IN, USA) and the geneticin from Gibco (Paisley, UK). Table 2 ). We then went on to investigate the effect of cannabidiol by itself on [ 35 S]GTPgS binding to mouse brain membranes. Although this compound had no detectable effect at 1 or 100 nM, it produced significant inhibition at 1 and 10 mM (Figure 3a) . The inhibitory effect produced by 1 mM cannabidiol did not deviate significantly from that of 1 mM rimonabant, whereas the inhibitory effect of 10 mM cannabidiol greatly exceeded that of 10 mM rimonabant (Po0.05; ANOVA followed by Bonferroni's multiple comparison test; n ¼ 6 and 8).
Results
Experiments with mouse brain membranes
Our next experiments were performed with the putative neutral CB 1 receptor antagonist, O-2654 (Thomas et al., 2004) , to establish how it compared with cannabidiol as a modulator of [ Table 1 . We also investigated whether cannabidiol would antagonize ligand-induced activation of a non-cannabinoid G protein-coupled receptor. More specifically, we addressed the question of whether cannabidiol can block the activation of opioid receptors by morphine as, like the CB 1 receptor, opioid receptors are thought to signal primarily through G i/o proteins (Corbett et al., 2006) . We selected morphine for these experiments as it is expected to target all the opioid Table 2 .
Cannabinoid antagonism by cannabidiol A Thomas et al receptor subtypes that are thought to be present in mouse brain membranes (Mignat et al., 1995 (Figure 7a ) and its apparent K B value was calculated to be 64.5 times less than its CB 2 K i value (Table 1) . Similar results were obtained from experiments with SR144528 performed under the same assay conditions (Figure 7b ). Thus, SR144528 induced a downward as well as rightward displacement of the CP55940 log concentrationresponse curve and exhibited an apparent K B value that was 15 times less than its CB 2 K i value (Table 1) .
We also investigated whether cannabidiol shares the ability of SR144528 to behave as a CB 2 receptor inverse agonist, as measured by inhibition of [ (Figure 8a) . The E max of cannabidiol did not deviate significantly from that of SR144528, whereas its pEC 50 (6.370.7) was markedly greater than that of SR144528 (9.170.3). A summary of these results can be found in Table 2 .
Experiments with O-2654 using human CB 2 -CHO cell membranes As O-2654 attenuated CP55940 responses in mouse brain membranes in a manner that is consistent with it being (Figure 7c ) was not markedly different from its CB 2 K i value (Table 1) . O-2654 appeared to induce downward as well as rightward displacements of the CP55940 log concentration-response curve in the hCB 2 -CHO cell membranes in these experiments (Figure 7c ). However, in contrast to our findings with cannabidiol and SR144528, this downward displacement was not statistically significant. Thus, the 95% CI for the bottom of the CP55940 log concentration-response curves in the absence or presence of 1 mM O-2654 overlapped. Although, we also discovered that when added by itself, O-2654 exhibits cannabidiol-like potency and efficacy as an inhibitor of [ 35 S]GTPgS binding to hCB 2 -CHO cell membranes (Table 2 and Figure 8b ), this should not be taken as evidence that O-2654 is a CB 2 receptor inverse agonist. Thus, the potency and efficacy of O-2654 as an inhibitor of [ 35 S]GTPgS binding remained the same irrespective of whether the bioassay was performed with hCB 2 -CHO cell membranes or with membranes from cells that had not been transfected with CB 2 receptors (n ¼ 6; Figure 9 ). In contrast, 
Discussion
The results described in this paper indicate that the unexpectedly high potency reported previously for cannabi- (Showalter et al., 1996; Thomas et al., 1998 Thomas et al., , 2004 Bisogno et al., 2001 see also Table 1 ). However, they are similar to the corresponding apparent K B values (34.0 and 120.3 nM, respectively) obtained for cannabidiol in the mouse vas deferens (Pertwee et al., 2002) , suggesting that this cannabinoid may be acting on the same target in the brain as in the vas deferens. Cannabidiol appears to exhibit at least some selectivity as an antagonist of CP55940 and R-( þ )-WIN55212, since 1 mM cannabidiol did not antagonize stimulation of [ 35 S]GTPgS binding to mouse brain membranes induced by the m-, d-and k-opioid receptor agonist, morphine (Mignat et al., 1995) . We have also found in a previous investigation (Pertwee et al., 2002) that cannabidiol is markedly less potent as an antagonist of DAMGO, a selective m-opioid receptor agonist, than as an antagonist of R-( þ )-WIN55212 or CP55940 in the mouse vas deferens. Although, cannabidiol has been reported to modulate allosterically m-and d-opioid receptors (Kathmann et al., 2006) , this occurs only at high micromolar concentrations and it is therefore unlikely that this interaction occurred in our experiments.
Rimonabant also exhibited greater potency as an antagonist of CP55940-and R-( þ )-WIN55212-induced stimulation of [ 35 S]GTPgS binding to mouse brain membranes than as a CB 1 receptor ligand. Thus, the apparent K B values of rimonabant for antagonism of these two cannabinoid receptor agonists were respectively 24 and 7 times lower than the K i of rimonabant for its displacement of [ 3 H]CP55940 from mouse brain membranes. Interestingly, such a K i /K B discrepancy has not been detected in the mouseisolated vas deferens (Pertwee et al., 1995) . This may be because rimonabant exhibits greater potency as an antagonist of CP55940 and R-( þ )-WIN55212 in brain tissue than in the vas deferens because first, R-( þ )-WIN55212 and CP55940 inhibit electrically evoked contractions of this tissue not only by acting through CB 1 receptors but also by activating non-CB 1 targets (see Pertwee et al., 2002 Pertwee et al., , 2005 Thomas et al., 2005) and because these putative non-CB 1 targets exhibit little or no sensitivity to antagonism by rimonabant.
By themselves, cannabidiol and rimonabant both inhibited [ (Petitet et al., 1998) .
The results from our experiments with membranes prepared from CB 1 -transfected and -untransfected CHO cells suggest that cannabidiol can inhibit [ Table 2 . rather than from MF1 mice may be because one or more of their targets was more highly expressed by the MF1 mice.
One question raised is whether cannabidiol was inhibiting [ 35 S]GTPgS binding to mouse brain membranes because, similar to rimonabant, it can block adenosine A 1 receptors when these are being activated by endogenously released adenosine (Savinainen et al., 2003) . Thus, Savinainen et al. (2003) have found that at a concentration of 1 mM, the selective A 1 receptor antagonist DPCPX prevents rimonabant from inhibiting [ 35 S]GTPgS binding to rat cerebellar membranes. Moreover, cannabidiol has recently been found to inhibit the cellular uptake of adenosine (Carrier et al., 2006) (Bouaboula et al., 1999; Portier et al., 1999; Ross et al., 1999; Rhee and Kim, 2002) , and this was confirmed by the results obtained in the present study with hCB 2 -CHO cell membranes. Cannabidiol also behaved as a CB 2 receptor inverse agonist as it shared the ability of SR144528 to induce an inhibition of [ There is evidence from the results obtained in this investigation that this antagonism of CP55940 by 1 mM cannabidiol in the hCB 2 -CHO cell membrane experiments may have been non-competitive in nature. Thus, 1 mM cannabidiol produced a marked downward displacement of the CP55940 log concentration-response curve for stimulation of [ (Figure 7a ) and re-analysis of these data in a manner expected to exclude the effect of cannabidiol by itself (see above) suggests that this downward displacement accounts entirely for the antagonism of CP55940 induced by 1 mM cannabidiol in the hCB 2 -CHO cell membrane experiments (Figure 10a ). In terms of the two-state model (Leff, 1995) , it may be that CP55940 stimulates [ 35 S]GTPgS binding to CB 2 receptors by shifting the equilibrium between constitutively active (R*) and inactive (R) receptors more towards R*, whereas cannabidiol shifts this equilibrium towards R, thereby 'physiologically' opposing the ability of CP55940 to stimulate CB 2 receptors. Hence at 1 mM, a concentration at which it induces little displacement of [ 3 H]CP55940 from hCB 2 receptors (Figure 6 ), cannabidiol may have been antagonizing CP55940 at the CB 2 receptors entirely through inverse agonism and not at all by direct competition with CP55940 for receptors in the R* state.
As to the antagonism of CP55940 induced by 100 nM SR144528 at the CB 2 receptor, this may have been partly competitive in nature and partly a result of inverse agonism. Thus, when the component of SR144528-induced antagonism of CP55940 that seemingly arises from its ability to inhibit [ 35 S]GTPgS binding to hCB 2 -CHO cell membranes was excluded, a significant SR144528-induced rightward shift in the log concentration-response curve of CP55940 was still apparent (Figure 10b) . Although, there still appears to be a downward displacement of the CP55940 log concentrationresponse curve, this was not found to be statistically significant. Thus, the 95% CI for the bottom of the CP55940 log concentration-response curves in the absence or presence of 100 nM SR144528 overlapped. The apparent K B value of SR144528 calculated from this shift is much closer to the CB 2 K i value of SR144528 than the corresponding apparent K B value calculated from the data shown in Figure 7b , however, this recalculated K B value of SR144528 remains significantly less than its CB 2 K i value. It is possible, therefore, that the E max of SR144528 for inhibiting [ 35 S]GTPgS binding to hCB 2 -CHO cell membranes underestimates its maximal inverse efficacy. This may be because an insufficient proportion of the hCB 2 receptors was constitutively active in the absence of CP55940, thereby making it possible for SR144528 to produce a further degree of inverse agonism in the presence of CP55940, which according to the two-state model would be expected to shift the equilibrium for CB 2 receptors from R to R* and so increase the number of CB 2 receptors in the putative constitutively active R* state (Leff, 1995) . This hypothesis is supported by results obtained with O-2654. This ligand does not appear to After this re-analysis, it was found that 1 mM cannabidiol did not produce a significant rightward shift of the CP55940 log concentrationresponse curve, whereas 100 nM SR144528 antagonized CP55940 with an apparent K B value of 2.5 nM, with 95% CI of 1.6 and 4.3 nM. (Table 1) . Further experiments will be required to test this hypothesis more fully and also to address the related question of whether the abilities of cannabidiol and rimonabant to behave as inverse agonists in mouse brain membranes accounts at least in part for our finding that these ligands antagonize CP55940-induced stimulation of [ (Table 1 ).
In conclusion, this paper provides evidence that cannabidiol exhibits unexpectedly high potency in vitro as an antagonist of both CB 1 and CB 2 receptor agonists and that this antagonism is non-competitive in nature. The mechanism by which cannabidiol antagonized CB 1 receptor agonists in our experiments remains to be elucidated, one possibility being that it can also attenuate any responses induced by CP55940 or R-( þ )-WIN55212 in brain membranes from CB 1 À/À mice. It is noteworthy, however, that Breivogel et al. (2001) have reported that in contrast to R-( þ )-WIN55212, CP55940 does not stimulate [ 35 S]GTPgS binding to such membranes. As to the high potency displayed by cannabidiol as an antagonist of CB 2 receptor activation, our data suggest that this may stem from its ability to induce CB 2 receptor inverse agonism at concentrations well below those at which it displaces [ 3 H]CP55940 from these receptors. This action may also contribute to the well-known anti-inflammatory properties of cannabidiol (reviewed in Pertwee, 2004) , as there is evidence that CB 2 receptor inverse agonism can inhibit immune cell migration (Lunn et al., 2006) . This paper also contains further evidence that O-2654 can behave as a neutral CB 1 receptor antagonist, at least at concentrations of up to 1 mM, whereas under the same assay conditions cannabidiol and the established inverse agonist, rimonabant, can behave as inverse agonists at concentrations of 1 and 10 mM. O-2654 may also be a neutral CB 2 receptor antagonist. Thus, although it inhibited [ 35 S]GTPgS binding to hCB 2 -CHO cell membranes, it appeared to do so in a CB 2 receptor-independent manner.
